Bufalin for an innovative therapeutic approach against cancer.

Bufalin; Bufalin (PubChem CID: 9547215); Cancer; Cardiotonic steroid; digoxin (PubChem CID: 2724385); marinobufagenin (PubChem CID: 11969465); ouabain (PubChem CID: 439501); Amphibian Venoms; Antineoplastic Agents; Bufanolides; Cardiac Glycosides; bufalin; Cell Line, Tumor; Cell Proliferation; Humans; Tumor Microenvironment; Amphibian Venoms/pharmacology; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Bufanolides/pharmacology; Bufanolides/therapeutic use; Cardiac Glycosides/pharmacology; Neoplasms/drug therapy; Neoplasms; Pharmacology

Abstract :

[en] Bufalin is an endogenous cardiotonic steroid, first discovered in toad venom but also found in the plasma of healthy humans, with anti-tumour activities in different cancer types. The current review is focused on its mechanisms of action and highlights its very large spectrum of effects both in vitro and in vivo. All leads to the conclusion that bufalin mediates its effects by affecting all the hallmarks of cancer and seems restricted to cancer cells avoiding side effects. Bufalin decreases cancer cell proliferation by acting on the cell cycle and inducing different mechanisms of cell death including apoptosis, necroptosis, autophagy and senescence. Bufalin also moderates metastasis formation by blocking migration and invasion as well as angiogenesis and by inducing a phenotype switch towards differentiation and decreasing cancer cell stemness. Regarding its various mechanisms of action in cancer cells, bufalin blocks overactivated signalling pathways and modifies cell metabolism. Moreover, bufalin gained lately a huge interest in the field of drug resistance by both reversing various drug resistance mechanisms and affecting the immune microenvironment. Together, these data support bufalin as a quite promising new anti-cancer drug candidate.

Disciplines :

Oncology

Author, co-author :

Soumoy, Laura ; Université de Mons - UMONS

Ghanem, Ghanem E; Laboratory of Clinical and Experimental Oncology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium

Saussez, Sven ; Université de Mons - UMONS

Journe, Fabrice ; Université de Mons - UMONS

Language :

English

Title :

Bufalin for an innovative therapeutic approach against cancer.

Publication date :

October 2022

Journal title :

Pharmacological Research

ISSN :

1043-6618

eISSN :

1096-1186

Publisher :

Academic Press, Netherlands

Volume :

184

Pages :

106442

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S1043661822003875?httpAccept=text/xml

Research unit :

M112 - Anatomie humaine et Oncologie expérimentale

Research institute :

R550 - Institut des Sciences et Technologies de la Santé

Funding text :

The authors would like to thank the “Health Institute” of the University of Mons and “Les amis de l′institut Bordet” for the funding. We also wish to acknowledge the University of Mons for funding full Ph.D. grant for Laura Soumoy.

Available on ORBi UMONS :

since 16 January 2023

Statistics

Number of views

23 (4 by UMONS)

Number of downloads

173 (1 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Botelho, A.F.M., Pierezan, F., Soto-Blanco, B., Melo, M.M., A review of cardiac glycosides: structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential. Toxicon Off. J. Int. Soc. Toxinol. 158 (2019), 63–68, 10.1016/j.toxicon.2018.11.429.
Bejček, J., Spiwok, V., Kmoníčková, E., Rimpelová, S., Na+/K+-ATPase revisited: on its mechanism of action, role in cancer, and activity modulation. Molecules, 26, 2021, 1905, 10.3390/molecules26071905.
Deng, L.-J., Li, Y., Qi, M., Liu, J.-S., Wang, S., Hu, L.-J., Lei, Y.-H., Jiang, R.-W., Chen, W.-M., Qi, Q., et al. Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment. Eur. J. Pharmacol., 887, 2020, 173379, 10.1016/j.ejphar.2020.173379.
Li, F.-J., Hu, J.-H., Ren, X., Zhou, C.-M., Liu, Q., Zhang, Y.-Q., Toad venom: a comprehensive review of chemical constituents, anticancer activities, and mechanisms. Arch. Pharm., 354, 2021, e2100060, 10.1002/ardp.202100060.
Mijatovic, T., Van Quaquebeke, E., Delest, B., Debeir, O., Darro, F., Kiss, R., Cardiotonic steroids on the road to anti-cancer therapy. Biochim. Biophys. Acta 1776 (2007), 32–57, 10.1016/j.bbcan.2007.06.002.
Cheng, C.-S., Wang, J., Chen, J., Kuo, K.T., Tang, J., Gao, H., Chen, L., Chen, Z., Meng, Z., New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of huachansu and its main active constituent bufalin. Cancer Cell Int., 19, 2019, 92, 10.1186/s12935-019-0806-1.
Utkin, Y.N., Animal venom studies: current benefits and future developments. World J. Biol. Chem. 6 (2015), 28–33, 10.4331/wjbc.v6.i2.28.
Rodriguez, C., Ibáñez, R., Rollins-Smith, L.A., Gutiérrez, M., Durant-Archibold, A.A., Antimicrobial secretions of toads (Anura, Bufonidae): bioactive extracts and isolated compounds against human pathogens. Antibiot. Basel Switz., 9, 2020, E843, 10.3390/antibiotics9120843.
Sousa, L.Q., de; Machado, K., da, C., Oliveira, S.F., de, C., Araújo, L., da, S., Monção-Filho, E.D.S., Melo-Cavalcante, A.A., de, C., Vieira-Júnior, G.M., Ferreira, P.M.P., Bufadienolides from amphibians: a promising source of anticancer prototypes for radical innovation, apoptosis triggering and Na+/K+-ATPase inhibition. Toxicon Off. J. Int. Soc. Toxinol. 127 (2017), 63–76, 10.1016/j.toxicon.2017.01.004.
Reznik, V.A., Kashkin, V.A., Agalakova, N.I., Adair, C.D., Bagrov, A.Y., Endogenous bufadienolides, fibrosis and preeclampsia. Cardiol. Res. Pract., 2019, 2019, 5019287, 10.1155/2019/5019287.
Oda, M., Kurosawa, M., Numazawa, S., Tanaka, S., Akizawa, T., Ito, K., Maeda, M., Yoshida, T., Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody. Life Sci. 68 (2001), 1107–1117, 10.1016/s0024-3205(00)01013-4.
Han, M., Yang, G., Lin, Q., Yang, Y., Zhang, H., Su, Y., Determination of endogenous bufalin in serum of patients with hepatocellular carcinoma based on HPLC-MS/MS. Front. Oncol., 9, 2019, 1572, 10.3389/fonc.2019.01572.
Meng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., Newman, R.A., Cohen, L., Liu, L., Thornton, B., et al. Pilot study of huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer 115 (2009), 5309–5318, 10.1002/cncr.24602.
Anderson, M.D., Cancer center a randomized, placebo-controlled, blinded phase II study of huachansu & gemcitabine in pancreatic cancer. Clin. Gov., 2012.
Meng, Z., Garrett, C.R., Shen, Y., Liu, L., Yang, P., Huo, Y., Zhao, Q., Spelman, A.R., Ng, C.S., Chang, D.Z., et al. Prospective randomised evaluation of traditional chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br. J. Cancer 107 (2012), 411–416, 10.1038/bjc.2012.283.
Zhai, X., Chen, Z., Li, B., Shen, F., Fan, J., Zhou, W., Yang, Y.-K., Xu, J., Qin, X., Li, L., et al. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J. Integr. Med. 11 (2013), 90–100, 10.3736/jintegrmed2013021.
Ling, C.-Q., Fan, J., Lin, H.-S., Shen, F., Xu, Z.-Y., Lin, L.-Z., Qin, S.-K., Zhou, W.-P., Zhai, X.-F., Li, B., et al. Clinical practice guidelines for the treatment of primary liver cancer with integrative Traditional Chinese and Western Medicine. J. Integr. Med. 16 (2018), 236–248, 10.1016/j.joim.2018.05.002.
Chen, Z., Zhai, X.-F., Su, Y.-H., Wan, X.-Y., Li, J., Xie, J.-M., Gao, B., Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer. Zhong Xi Yi Jie He Xue Bao 1 (2003), 184–186, 10.3736/jcim20030311.
Tan, X., Liang, X., Xi, J., Guo, S., Meng, M., Chen, X., Li, Y., Clinical efficacy and safety of Huachansu Injection Combination with platinum-based chemotherapy for advanced non-small cell lung cancer. Medicine, 100, 2021, e27161, 10.1097/MD.0000000000027161.
Jiang, Y., Liu, L.-S., Shen, L.-P., Han, Z.-F., Jian, H., Liu, J.-X., Xu, L., Li, H.-G., Tian, J.-H., Mao, Z.-J., Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement. Ther. Med. 24 (2016), 55–62, 10.1016/j.ctim.2015.12.006.
Jiang, Y., Wu, L.B., Shen, L.P., Zhang, P., Jiang, W.J., Tian, J.H., Liu, L.S., Effect of traditional Chinese medicine treatment as maintenance therapy on regulating the serum concentration of sCTLA-4 in patients with advanced non-small-cell lung cancer and its relationship with prognosis. Zhonghua Zhong Liu Za Zhi 38 (2016), 757–762, 10.3760/cma.j.issn.0253-3766.2016.10.009.
Wu, J., Zhang, D., Ni, M., Xue, J., Wang, K., Duan, X., Liu, S., Effectiveness of huachansu injection combined with chemotherapy for treatment of gastric cancer in China: a systematic review and meta-analysis. J. Tradit. Chin. Med. Chung Tsa Chih Ying Wen Pan 40 (2020), 749–757, 10.19852/j.cnki.jtcm.2020.05.004.
Qin, T.-J., Zhao, X.-H., Yun, J., Zhang, L.-X., Ruan, Z.-P., Pan, B.-R., Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J. Gastroenterol. 14 (2008), 5210–5216, 10.3748/wjg.14.5210.
Gu, R., Zhang, Q., Effects of low-dose bufalin combined with hydroxycamptothecin on human castration-resistant prostate cancer xenografts in nude mice. Exp. Ther. Med., 22, 2021, 1015, 10.3892/etm.2021.10447.
Chen, F., Zhu, L., Hu, J., Jiang, S., Liu, H., Zheng, J., Wang, J., Wang, F., Li, Z., Bufalin attenuates triple-negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4. Oncol. Lett., 20, 2020, 171, 10.3892/ol.2020.12028.
Liu, X., Zhou, Y., Peng, J., Xie, B., Shou, Q., Wang, J., Silencing C-Myc enhances the antitumor activity of bufalin by suppressing the HIF-1α/SDF-1/CXCR4 pathway in pancreatic cancer cells. Front. Pharmacol., 11, 2020, 495, 10.3389/fphar.2020.00495.
Tsai, S.-C., Yang, J.-S., Peng, S.-F., Lu, C.-C., Chiang, J.-H., Chung, J.-G., Lin, M.-W., Lin, J.-K., Amagaya, S., Wai-Shan Chung, C., et al. Bufalin increases sensitivity to AKT/MTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int. J. Oncol. 41 (2012), 1431–1442, 10.3892/ijo.2012.1579.
Sun, X., Ng, T.T.H., Sham, K.W.Y., Zhang, L., Chan, M.T.V., Wu, W.K.K., Cheng, C.H.K., Bufalin, a Traditional Chinese Medicine Compound, prevents tumor formation in two murine models of colorectal cancer. Cancer Prev. Res. Phila. Pa 12 (2019), 653–666, 10.1158/1940-6207.CAPR-19-0134.
Wu, S.-H., Hsiao, Y.-T., Chen, J.-C., Lin, J.-H., Hsu, S.-C., Hsia, T.-C., Yang, S.-T., Hsu, W.-H., Chung, J.-G., Bufalin alters gene expressions associated DNA damage, cell cycle, and apoptosis in human lung cancer NCI-H460 cells in vitro. Mol. Basel Switz. 19 (2014), 6047–6057, 10.3390/molecules19056047.
Wu, D., Zhou, W.-Y., Lin, X.-T., Fang, L., Xie, C.-M., Bufalin induces apoptosis via mitochondrial ROS-mediated caspase-3 activation in HCT-116 and SW620 human colon cancer cells. Drug Chem. Toxicol. 42 (2019), 444–450, 10.1080/01480545.2018.1512611.
Tsai, S.-C., Lu, C.-C., Lee, C.-Y., Lin, Y.-C., Chung, J.-G., Kuo, S.-C., Amagaya, S., Chen, F.-N., Chen, M.Y., Chan, S.-F., et al. AKT serine/threonine protein kinase modulates bufalin-triggered intrinsic pathway of apoptosis in CAL 27 human oral cancer cells. Int. J. Oncol. 41 (2012), 1683–1692, 10.3892/ijo.2012.1605.
Qi, F., Inagaki, Y., Gao, B., Cui, X., Xu, H., Kokudo, N., Li, A., Tang, W., Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via fas- and mitochondria-mediated pathways. Cancer Sci. 102 (2011), 951–958, 10.1111/j.1349-7006.2011.01900.x.
Sun, L., Chen, T., Wang, X., Chen, Y., Wei, X., Bufalin induces reactive oxygen species dependent bax translocation and apoptosis in ASTC-a-1 cells. Evid. Based Complement. Altern. Med. ECAM, 2011, 2011, 249090, 10.1093/ecam/nep082.
Yu, C.-H., Kan, S.-F., Pu, H.-F., Jea Chien, E., Wang, P.S., Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 99 (2008), 2467–2476, 10.1111/j.1349-7006.2008.00966.x.
Wu, S.-H., Bau, D.-T., Hsiao, Y.-T., Lu, K.-W., Hsia, T.-C., Lien, J.-C., Ko, Y.-C., Hsu, W.-H., Yang, S.-T., Huang, Y.-P., et al. Bufalin induces apoptosis in vitro and has antitumor activity against human lung cancer xenografts in vivo. Environ. Toxicol. 32 (2017), 1305–1317, 10.1002/tox.22325.
Kang, K.-H., Han, M.H., Jeong, J.-W., Park, C., Lee, S.-H., Lee, H.W., Hong, S.H., Choi, Y.H., Hong, S.H., Bufalin sensitizes human bladder carcinoma cells to TRAIL-mediated apoptosis. Oncol. Lett. 14 (2017), 853–859, 10.3892/ol.2017.6223.
Li, Y., Tian, X., Liu, X., Gong, P., Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Carcinogenesis 39 (2018), 700–707, 10.1093/carcin/bgy039.
Hong, S.-H., Choi, Y.H., Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol. Rep. 27 (2012), 114–120, 10.3892/or.2011.1451.
Huang, H., Cao, Y., Wei, W., Liu, W., Lu, S.-Y., Chen, Y.-B., Wang, Y., Yan, H., Wu, Y.-L., Targeting poly (ADP-Ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells. PLoS One, 8, 2013, e66130, 10.1371/journal.pone.0066130.
Wang, J., Chen, C., Wang, S., Zhang, Y., Yin, P., Gao, Z., Xu, J., Feng, D., Zuo, Q., Zhao, R., et al. Bufalin inhibits HCT116 colon cancer cells and its orthotopic xenograft tumor in mice model through genes related to apoptotic and PTEN/AKT pathways. Gastroenterol. Res. Pract., 2015, 2015, 457193, 10.1155/2015/457193.
Gu, W., Han, K., Su, Y., Huang, X., Ling, C., Inhibition action of bufalin on human transplanted hepatocellular tumor and its effects on expressions of Bcl-2 and Bax proteins in nude mice. Zhong Xi Yi Jie He Xue Bao 5 (2007), 155–159, 10.3736/jcim20070211.
Xie, X., Yin, J., Wen, L., Gao, Z., Zou, C., Wang, J., Huang, G., Tang, Q., Colombo, C., He, W., et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS One, 7, 2012, e47375, 10.1371/journal.pone.0047375.
Kang, X.-H., Zhang, J.-H., Zhang, Q.-Q., Cui, Y.-H., Wang, Y., Kou, W.-Z., Miao, Z.-H., Lu, P., Wang, L.-F., Xu, Z.-Y., et al. Degradation of Mcl-1 through GSK-3β activation regulates apoptosis induced by bufalin in non-small cell lung cancer H1975 cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 41 (2017), 2067–2076, 10.1159/000475438.
Qian, L., Su, H., Wang, G., Li, B., Shen, G., Gao, Q., Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J. Cancer 11 (2020), 3114–3123, 10.7150/jca.38393.
Dong, Y., Yin, S., Li, J., Jiang, C., Ye, M., Hu, H., Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis Int. J. Program. Cell Death 16 (2011), 394–403, 10.1007/s10495-011-0573-5.
Liu, Y., Wang, X., Jia, Y., Liu, Y., Effects of bufalin on the MTOR/P70S6K pathway and apoptosis in esophageal squamous cell carcinoma in nude mice. Int. J. Mol. Med. 40 (2017), 357–366, 10.3892/ijmm.2017.3039.
Zhang, Y., Dong, Y., Melkus, M.W., Yin, S., Tang, S.-N., Jiang, P., Pramanik, K., Wu, W., Kim, S., Ye, M., et al. Role of P53-senescence induction in suppression of LNCaP prostate cancer growth by cardiotonic compound bufalin. Mol. Cancer Ther. 17 (2018), 2341–2352, 10.1158/1535-7163.MCT-17-1296.
Lan, Y.-L., Zou, Y.-J., Lou, J.-C., Xing, J.-S., Wang, X., Zou, S., Ma, B.-B., Ding, Y., Zhang, B., The sodium pump Α1 subunit regulates bufalin sensitivity of human glioblastoma cells through the P53 signaling pathway. Cell Biol. Toxicol. 35 (2019), 521–539, 10.1007/s10565-019-09462-y.
Li, Y., Zhang, Y., Wang, X., Yang, Q., Zhou, X., Wu, J., Yang, X., Zhao, Y., Lin, R., Xie, Y., et al. Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating annexin A2 and DRP1 protein expression. Cancer Cell Int., 21, 2021, 424, 10.1186/s12935-021-02137-x.
Shen, S., Zhang, Y., Wang, Z., Liu, R., Gong, X., Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. Int. J. Biol. Sci. 10 (2014), 212–224, 10.7150/ijbs.8056.
Chen, Y., Li, M., Li, Z., Gao, P., Zhou, X., Zhang, J., Bufalin induces apoptosis in the U‑2OS human osteosarcoma cell line via triggering the mitochondrial pathway. Mol. Med. Rep. 13 (2016), 817–822, 10.3892/mmr.2015.4583.
Song, J., Zou, D., Zhao, X., Chen, Y., Lv, F., Wang, S., Sui, D., Han, Q., Yang, C., Wang, X., et al. Bufalin inhibits human diffuse large B-Cell lymphoma tumorigenesis by inducing cell death through the Ca2+/NFATC1/CMYC pathway. Carcinogenesis 42 (2021), 303–314, 10.1093/carcin/bgaa108.
Hsiao, Y.-P., Yu, C.-S., Yu, C.-C., Yang, J.-S., Chiang, J.-H., Lu, C.-C., Huang, H.-Y., Tang, N.-Y., Yang, J.-H., Huang, A.-C., et al. Triggering apoptotic death of human malignant melanoma A375.S2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid. Based Complement. Altern. Med. ECAM, 2012(591241), 2012, 10.1155/2012/591241.
Su, E.-Y., Chu, Y.-L., Chueh, F.-S., Ma, Y.-S., Peng, S.-F., Huang, W.-W., Liao, C.-L., Huang, A.-C., Chung, J.-G., Bufalin induces apoptotic cell death in human nasopharyngeal carcinoma cells through mitochondrial ROS and TRAIL pathways. Am. J. Chin. Med. 47 (2019), 237–257, 10.1142/S0192415×19500125.
Huang, W.-W., Yang, J.-S., Pai, S.-J., Wu, P.-P., Chang, S.-J., Chueh, F.-S., Fan, M.-J., Chiou, S.-M., Kuo, H.-M., Yeh, C.-C., et al. Bufalin Induces G0/G1 phase arrest through inhibiting the levels of cyclin D, Cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat. Res. 732 (2012), 26–33, 10.1016/j.mrfmmm.2011.09.010.
Zhu, Z., Li, E., Liu, Y., Gao, Y., Sun, H., Ma, G., Wang, Z., Liu, X., Wang, Q., Qu, X., et al. Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells. World J. Surg. Oncol., 10, 2012, 228, 10.1186/1477-7819-10-228.
Zhang, N., Xie, Y., Tai, Y., Gao, Y., Guo, W., Yu, W., Li, J., Feng, X., Hao, J., Gao, Y., et al. Bufalin inhibits HTERT expression and colorectal cancer cell growth by targeting CPSF4. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharm. 40 (2016), 1559–1569, 10.1159/000453206.
Abdelfatah, S., Lu, X., Schmeda-Hirschmann, G., Efferth, T., Cytotoxicity and antimitotic activity of Rhinella schneideri and Rhinella marina venoms. J. Ethnopharmacol., 242, 2019, 112049, 10.1016/j.jep.2019.112049.
Chou, H.-Y., Chueh, F.-S., Ma, Y.-S., Wu, R.S.-C., Liao, C.-L., Chu, Y.-L., Fan, M.-J., Huang, W.-W., Chung, J.-G., Bufalin induced apoptosis in SCC‑4 human tongue cancer cells by decreasing Bcl‑2 and increasing bax expression via the mitochondria‑dependent pathway. Mol. Med. Rep. 16 (2017), 7959–7966, 10.3892/mmr.2017.7651.
Zhao, H., Li, Q., Pang, J., Jin, H., Li, H., Yang, X., Blocking autophagy enhances the pro-apoptotic effect of bufalin on human gastric cancer cells through endoplasmic reticulum stress. Biol. Open 6 (2017), 1416–1422, 10.1242/bio.026344.
Gu, W., Liu, L., Fang, F.-F., Huang, F., Cheng, B.-B., Li, B., Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Oncol. Rep. 31 (2014), 216–222, 10.3892/or.2013.2817.
Lee, C.-H., Shih, Y.-L., Lee, M.-H., Au, M.-K., Chen, Y.-L., Lu, H.-F., Chung, J.-G., Bufalin induces apoptosis of human osteosarcoma U-2 OS cells through endoplasmic reticulum stress, caspase- and mitochondria-dependent signaling pathways. Mol. Basel Switz., 22, 2017, E437, 10.3390/molecules22030437.
Yin, J.-Q., Shen, J.-N., Su, W.-W., Wang, J., Huang, G., Jin, S., Guo, Q.-C., Zou, C.-Y., Li, H.-M., Li, F.-B., Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol. Sin. 28 (2007), 712–720, 10.1111/j.1745-7254.2007.00559.x.
Yan, S., Qu, X., Xu, C., Zhu, Z., Zhang, L., Xu, L., Song, N., Teng, Y., Liu, Y., Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J. Cancer Res. Clin. Oncol. 138 (2012), 1279–1289, 10.1007/s00432-012-1204-4.
Yan, S., Qu, X., Xu, L., Che, X., Ma, Y., Zhang, L., Teng, Y., Zou, H., Liu, Y., Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs 25 (2014), 683–689, 10.1097/CAD.0000000000000095.
Pan, L., Nie, L., Yao, S., Bi, A., Ye, Y., Wu, Y., Tan, Z., Wu, Z., Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport Chain. Int. J. Mol. Med. 46 (2020), 2137–2149, 10.3892/ijmm.2020.4745.
Tian, X., Dai, S., Sun, J., Jiang, S., Sui, C., Meng, F., Li, Y., Fu, L., Jiang, T., Wang, Y., et al. Bufalin induces mitochondria-dependent apoptosis in pancreatic and oral cancer cells by downregulating HTERT expression via activation of the JNK/P38 pathway. Evid. Based Complement. Altern. Med. ECAM, 2015, 2015, 546210, 10.1155/2015/546210.
Xie, X.-B., Wen, L.-L., Yin, J.-Q., Liao, H.-Y., Zou, C.-Y., Wang, B., Huang, G., Shen, J.-N., Proteomics research of bufalin-induced apoptosis in osteosarcoma cell lines. Zhongguo Zhong Yao Za Zhi Zhongguo Zhongyao Zazhi China J. Chin. Mater. Med. 39 (2014), 2739–2743.
Li, Y., Gong, P., Kong, C., Tian, X., Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the RIP1/RIP3/PGAM5 pathway. Anticancer Drugs, 30, 2019, e0770, 10.1097/CAD.0000000000000770.
Liu, X.-D., Song, C.-Y., Kong, C.-C., Tian, X., Bufalin induces programmed necroptosis in triple-negative breast cancer drug-resistant cell lines through RIP1/ROS-mediated pathway. Chin. J. Integr. Med., 2021, 10.1007/s11655-021-3458-7.
LingHu, H.R., Luo, H., Gang, L., Bufalin induces glioma cell death by apoptosis or necroptosis. OncoTargets Ther. 13 (2020), 4767–4778, 10.2147/OTT.S242567.
Qi, H.-Y., Qu, X.-J., Liu, J., Hou, K.-Z., Fan, Y.-B., Che, X.-F., Liu, Y.-P., Bufalin induces protective autophagy by Cbl-b Regulating MTOR and ERK signaling pathways in gastric cancer cells. Cell Biol. Int. 43 (2019), 33–43, 10.1002/cbin.11076.
Sheng, X., Zhu, P., Qin, J., Li, Q., The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin. Oncol. Rep. 39 (2018), 2931–2941, 10.3892/or.2018.6365.
Xie, C.-M., Chan, W.Y., Yu, S., Zhao, J., Cheng, C.H.K., Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic. Biol. Med. 51 (2011), 1365–1375, 10.1016/j.freeradbiomed.2011.06.016.
Miao, Q., Bi, L.-L., Li, X., Miao, S., Zhang, J., Zhang, S., Yang, Q., Xie, Y.-H., Zhang, J., Wang, S.-W., Anticancer effects of bufalin on human hepatocellular carcinoma HepG2 cells: roles of apoptosis and autophagy. Int. J. Mol. Sci. 14 (2013), 1370–1382, 10.3390/ijms14011370.
Hu, F., Han, J., Zhai, B., Ming, X., Zhuang, L., Liu, Y., Pan, S., Liu, T., Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis Int. J. Program. Cell Death 19 (2014), 210–223, 10.1007/s10495-013-0914-7.
Wu, X.-Y., Tian, F., Su, M.-H., Wu, M., Huang, Y., Hu, L.-H., Jin, L., Zhu, X.-J., BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway. Int. Immunopharmacol. 64 (2018), 24–32, 10.1016/j.intimp.2018.08.016.
Yang, H., Liu, Y., Zhao, M.-M., Guo, Q., Zheng, X.-K., Liu, D., Zeng, K.-W., Tu, P.-F., Therapeutic potential of targeting membrane-spanning proteoglycan SDC4 in hepatocellular carcinoma. Cell Death Dis., 12, 2021, 492, 10.1038/s41419-021-03780-y.
Jing, Y., Watabe, M., Hashimoto, S., Nakajo, S., Nakaya, K., Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res. 14 (1994), 1193–1198.
Yang, L., Zhou, F., Zhuang, Y., Liu, Y., Xu, L., Zhao, H., Xiang, Y., Dai, X., Liu, Z., Huang, X., et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway. Br. J. Cancer 124 (2021), 645–657, 10.1038/s41416-020-01135-6.
Xie, C.-M., Liu, X.-Y., Yu, S., Cheng, C.H.K., Cardiac glycosides block cancer growth through HIF-1α- and NF-ΚB-mediated Plk1. Carcinogenesis 34 (2013), 1870–1880, 10.1093/carcin/bgt136.
Xie, C.-M., Lin, X.-T., Wu, D., Tan, Y., Cheng, C.H.K., Zhang, J., Cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway. Oncotarget 9 (2018), 13783–13795, 10.18632/oncotarget.24475.
Yu, Z., Feng, H., Sun, X., Zhuo, Y., Li, M., Zhou, Z., Huang, L., Jiang, Y., Zhu, X., Zhang, X., et al. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase. Sci. Rep., 8, 2018, 3891, 10.1038/s41598-018-22113-2.
Wu, S.-H., Wu, T.-Y., Hsiao, Y.-T., Lin, J.-H., Hsu, S.-C., Hsia, T.-C., Yang, S.-T., Hsu, W.-H., Chung, J.-G., Bufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways. Am. J. Chin. Med. 42 (2014), 729–742, 10.1142/S0192415×14500475.
Hsu, C.-M., Tsai, Y., Wan, L., Tsai, F.-J., Bufalin Induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. Int. J. Oncol. 43 (2013), 338–348, 10.3892/ijo.2013.1942.
Xie, J., Lin, W., Huang, L., Xu, N., Xu, A., Chen, B., Watanabe, M., Liu, C., Huang, P., Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/MTOR signaling pathway. Oncol. Lett. 16 (2018), 3867–3873, 10.3892/ol.2018.9111.
Tian, X., Luo, Y., Yan, Y., Sui, C., Meng, F., Liu, Y., Effect of bufalin on cellular proliferation and apoptosis in human esophageal squamous carcinoma EC9706 cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 34 (2012), 556–562, 10.3881/j.issn.1000-503X.2012.06.004.
Zhang, X., Huang, Q., Wang, X., Xu, Y., Xu, R., Han, M., Huang, B., Chen, A., Qiu, C., Sun, T., et al. Bufalin enhances radiosensitivity of glioblastoma by suppressing mitochondrial function and DNA damage repair. Biomed. Pharmacother. Biomed. Pharmacother. 94 (2017), 627–635, 10.1016/j.biopha.2017.07.136.
Takai, N., Ueda, T., Nishida, M., Nasu, K., Narahara, H., Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int. J. Mol. Med. 21 (2008), 637–643.
Zhang, Z.-J., Yang, Y.-K., Wu, W.-Z., Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice. J. Transl. Med., 12, 2014, 57, 10.1186/1479-5876-12-57.
Gai, J.Q., Sheng, X., Qin, J.M., Sun, K., Zhao, W., Ni, L., The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway. Int. J. Oncol. 48 (2016), 338–348, 10.3892/ijo.2015.3250.
Qiu, D.-Z., Zhang, Z.-J., Wu, W.-Z., Yang, Y.-K., Bufalin, a component in chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complement. Altern. Med., 13, 2013, 185, 10.1186/1472-6882-13-185.
Su, S., Dou, H., Wang, Z., Zhang, Q., Bufalin inhibits ovarian carcinoma via targeting MTOR/HIF-α pathway. Basic Clin. Pharmacol. Toxicol. 128 (2021), 224–233, 10.1111/bcpt.13487.
Chen, Y.-Y., Lu, H.-F., Hsu, S.-C., Kuo, C.-L., Chang, S.-J., Lin, J.-J., Wu, P.-P., Liu, J.-Y., Lee, C.-H., Chung, J.-G., et al. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-KB and matrix metalloproteinase-2/-9-signaling pathways. Environ. Toxicol. 30 (2015), 74–82, 10.1002/tox.21896.
Hong, S.H., Kim, G.-Y., Chang, Y.-C., Moon, S.-K., Kim, W.-J., Choi, Y.H., Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions. Int. J. Oncol. 42 (2013), 277–286, 10.3892/ijo.2012.1683.
Li, H., Wang, P., Gao, Y., Zhu, X., Liu, L., Cohen, L., Meng, Z., Yang, P., Na+/K+-ATPase Α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol. Rep. 25 (2011), 825–830, 10.3892/or.2010.1120.
Watabe, M., Masuda, Y., Nakajo, S., Yoshida, T., Kuroiwa, Y., Nakaya, K., The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J. Biol. Chem. 271 (1996), 14067–14072, 10.1074/jbc.271.24.14067.
Watabe, M., Ito, K., Masuda, Y., Nakajo, S., Nakaya, K., Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16 (1998), 779–787, 10.1038/sj.onc.1201592.
Sheng, X., Sun, X., Sun, K., Sui, H., Qin, J., Li, Q., Inhibitory effect of bufalin combined with hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells. Int. J. Oncol. 49 (2016), 1513–1524, 10.3892/ijo.2016.3667.
Song, X., Zhang, C., Zhao, M., Chen, H., Liu, X., Chen, J., Lonard, D.M., Qin, L., Xu, J., Wang, X., et al. Steroid receptor coactivator-3 (SRC-3/AIB1) as a novel therapeutic target in triple negative breast cancer and its inhibition with a phospho-bufalin prodrug. PLoS One, 10, 2015, e0140011, 10.1371/journal.pone.0140011.
Zou, Z., Luo, X., Nie, P., Wu, B., Zhang, T., Wei, Y., Wang, W., Geng, G., Jiang, J., Mi, Y., Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 478 (2016), 227–233, 10.1016/j.bbrc.2016.07.063.
Wang, Y., Lonard, D.M., Yu, Y., Chow, D.-C., Palzkill, T.G., Wang, J., Qi, R., Matzuk, A.J., Song, X., Madoux, F., et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 74 (2014), 1506–1517, 10.1158/0008-5472.CAN-13-2939.
Gong, M., Wang, X., Mu, L., Wang, Y., Pan, J., Yuan, X., Zhou, H., Xing, J., Wang, R., Sun, J., et al. Steroid receptor coactivator-1 enhances the stemness of glioblastoma by activating long noncoding RNA XIST/MiR-152/KLF4 pathway. Cancer Sci. 112 (2021), 604–618, 10.1111/cas.14685.
Chen, J., Wang, H., Jia, L., He, J., Li, Y., Liu, H., Wu, R., Qiu, Y., Zhan, Y., Yuan, Z., et al. Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer. Cancer Lett. 513 (2021), 63–74, 10.1016/j.canlet.2021.05.008.
Chen, Y., Guo, Q., Zhang, B., Kang, M., Xie, Q., Wu, Y., Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncol. Lett. 4 (2012), 792–798, 10.3892/ol.2012.783.
Dou, L., Zou, D., Song, F., Jin, Y., Li, Y., Zhang, Y., Bufalin suppresses ovarian cancer cell proliferation via EGFR pathway. Chin. Med. J., 2021, 10.1097/CM9.0000000000001879.
Kim, N.-Y., Suh, Y.-A., Kim, S., Lee, C., Bufalin down-regulates axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells. Biosci. Rep., 40, 2020, 10.1042/BSR20193959.
Wu, S.-H., Hsiao, Y.-T., Kuo, C.-L., Yu, F.-S., Hsu, S.-C., Wu, P.-P., Chen, J.-C., Hsia, T.-C., Liu, H.-C., Hsu, W.-H., et al. Bufalin inhibits NCI-H460 human lung cancer cell metastasis in vitro by inhibiting MAPKs, MMPs, and NF-ΚB pathways. Am. J. Chin. Med. 43 (2015), 1247–1264, 10.1142/S0192415×15500718.
Zhu, Z., Sun, H., Ma, G., Wang, Z., Li, E., Liu, Y., Liu, Y., Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway. Int. J. Mol. Sci. 13 (2012), 2025–2035, 10.3390/ijms13022025.
Gao, Y., Li, H.-X., Xu, L.-T., Wang, P., Xu, L.-Y., Cohen, L., Yang, P.-Y., Gu, K., Meng, Z.-Q., Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol. Biol. Rep. 39 (2012), 1683–1689, 10.1007/s11033-011-0908-x.
Zou, D., Song, J., Deng, M., Ma, Y., Yang, C., Liu, J., Wang, S., Wen, Z., Tang, Y., Qu, X., et al. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway. FASEB J. Publ. Fed. Am. Soc. Exp. Biol., 35, 2021, e21601, 10.1096/fj.202002780R.
Chueh, F.-S., Chen, Y.-Y., Huang, A.-C., Ho, H.-C., Liao, C.-L., Yang, J.-S., Kuo, C.-L., Chung, J.-G., Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environ. Toxicol. 29 (2014), 21–29, 10.1002/tox.20769.
Howard, C.M., Estrada, M., Terrero, D., Tiwari, A.K., Raman, D., Identification of cardiac glycosides as novel inhibitors of EIF4A1-mediated translation in triple-negative breast cancer cells. Cancers, 12, 2020, E2169, 10.3390/cancers12082169.
Liu, M., Feng, L.-X., Sun, P., Liu, W., Mi, T., Lei, M., Wu, W., Jiang, B., Yang, M., Hu, L., et al. Knockdown of Apolipoprotein E enhanced sensitivity of Hep3B cells to cardiac steroids via regulating Na +/K + -ATPase signalosome. Mol. Cancer Ther. 15 (2016), 2955–2965, 10.1158/1535-7163.MCT-15-0961.
Soumoy, L., Wells, M., Najem, A., Krayem, M., Ghanem, G., Hambye, S., Saussez, S., Blankert, B., Journe, F., Toad venom antiproliferative activities on metastatic melanoma: bio-guided fractionation and screening of the compounds of two different venoms. Biology, 9, 2020, E218, 10.3390/biology9080218.
Lan, Y.-L., Wang, X., Lou, J.-C., Xing, J.-S., Yu, Z.-L., Wang, H., Zou, S., Ma, X., Zhang, B., Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na+/K+-ATPase Α1 subunit. Biomed. Pharmacother. Biomed. Pharmacother. 103 (2018), 204–215, 10.1016/j.biopha.2018.04.030.
Lin, Y., Ho, D.H., Newman, R.A., Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunitst. J. Exp. Ther. Oncol. 8 (2010), 271–286.
Huang, H., Zhang, W., Bufalin induced apoptosis of bladder carcinoma cells through the inactivation of Na+K+-ATPase. Oncol. Lett. 16 (2018), 3826–3832, 10.3892/ol.2018.9142.
Li, H., Hu, S., Pang, Y., Li, M., Chen, L., Liu, F., Liu, M., Wang, Z., Cheng, X., Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of integrin Β2/FAK signaling pathway in ovarian cancer. Am. J. Cancer Res. 8 (2018), 1288–1296.
Zhang, J., Hong, Y., Xie, P., Chen, Y., Jiang, L., Yang, Z., Cao, G., Chen, Z., Liu, X., Chen, Y., et al. Spatial lipidomics reveals anticancer mechanisms of bufalin in combination with cinobufagin in tumor-bearing mice. Front. Pharmacol., 11, 2021, 593815, 10.3389/fphar.2020.593815.
Zhang, J., Hong, Y., Jiang, L., Yi, X., Chen, Y., Liu, L., Chen, Z., Wu, Y., Cai, Z., Global metabolomic and lipidomic analysis reveal the synergistic effect of bufalin in combination with cinobufagin against HepG2 cells. J. Proteome Res. 19 (2020), 873–883, 10.1021/acs.jproteome.9b00681.
Zhan, Y., Qiu, Y., Wang, H., Wang, Z., Xu, J., Fan, G., Xu, J., Li, W., Cao, Y., Le, V.-M., et al. Bufalin reverses multidrug resistance by regulating stemness through the CD133/Nuclear factor-ΚB/MDR1 pathway in colorectal cancer. Cancer Sci. 111 (2020), 1619–1630, 10.1111/cas.14345.
Yuan, Z.-T., Shi, X.-J., Yuan, Y.-X., Qiu, Y.-Y., Zou, Y., Liu, C., Yu, H., He, X., Xu, K., Yin, P.-H., Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer. Oncotarget 8 (2017), 48012–48026, 10.18632/oncotarget.18225.
Zhai, X., Lu, J., Wang, Y., Fang, F., Li, B., Gu, W., Reversal effect of bufalin on multidrug resistance in K562/VCR vincristine-resistant leukemia cell line. J. Tradit. Chin. Med. Chung Tsa Chih Ying Wen Pan 34 (2014), 678–683, 10.1016/s0254-6272(15)30082-0.
Dai, X.-Y., Zhou, B.-F., Xie, Y.-Y., Lou, J., Li, K.-Q., Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells. Oncol. Lett. 15 (2018), 8019–8026, 10.3892/ol.2018.8332.
Sun, J., Xu, K., Qiu, Y., Gao, H., Xu, J., Tang, Q., Yin, P., Bufalin reverses acquired drug resistance by inhibiting stemness in colorectal cancer cells. Oncol. Rep. 38 (2017), 1420–1430, 10.3892/or.2017.5826.
Yu, Z., Feng, H., Zhuo, Y., Li, M., Zhu, X., Huang, L., Zhang, X., Zhou, Z., Zheng, C., Jiang, Y., et al. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation. Cell. Oncol. Dordr. 43 (2020), 1129–1145, 10.1007/s13402-020-00546-0.
Wang, H., Zhang, C., Chi, H., Meng, Z., Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. Mol. Med. Rep. 17 (2018), 8101–8110, 10.3892/mmr.2018.8927.
Zhai, B., Hu, F., Yan, H., Zhao, D., Jin, X., Fang, T., Pan, S., Sun, X., Xu, L., Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress. PLoS One, 10, 2015, e0138485, 10.1371/journal.pone.0138485.
Wang, H., Zhang, C., Chi, H., Meng, Z., Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting MTOR/VEGF signaling. Int. J. Oncol. 52 (2018), 2051–2060, 10.3892/ijo.2018.4351.
Zhao, H., Zhao, D., Jin, H., Li, H., Yang, X., Zhuang, L., Liu, T., Bufalin reverses intrinsic and acquired drug resistance to cisplatin through the AKT signaling pathway in gastric cancer cells. Mol. Med. Rep. 14 (2016), 1817–1822, 10.3892/mmr.2016.5426.
Liu, F., Tong, D., Li, H., Liu, M., Li, J., Wang, Z., Cheng, X., Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin Α2/Β5/FAK signaling pathway. Oncotarget 7 (2016), 8896–8907, 10.18632/oncotarget.6840.
Liu, J., Zhang, Y., Sun, S., Zhang, G., Jiang, K., Sun, P., Zhang, Y., Yao, B., Sui, R., Chen, Y., et al. Bufalin induces apoptosis and improves the sensitivity of human glioma stem-like cells to temozolamide. Oncol. Res. 27 (2019), 475–486, 10.3727/096504018×15270916676926.
Zhu, Z., Li, E., Liu, Y., Gao, Y., Sun, H., Wang, Y., Wang, Z., Liu, X., Wang, Q., Liu, Y., Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression. Acta Haematol. 128 (2012), 144–150, 10.1159/000339424.
Ning, Z., Zhu, Z., Wang, H., Zhang, C., Xu, L., Zhuang, L., Yan, X., Wang, D., Wang, P., Meng, Z., High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells. OncoTargets Ther. 12 (2019), 1161–1170, 10.2147/OTT.S185953.
Zhang, J.-J., Zhou, X.-H., Zhou, Y., Wang, Y.-G., Qian, B.-Z., He, A.-N., Shen, Z., Hu, H.-Y., Yao, Y., Bufalin suppresses the migration and invasion of prostate cancer cells through HOTAIR, the Sponge of MiR-520b. Acta Pharmacol. Sin. 40 (2019), 1228–1236, 10.1038/s41401-019-0234-8.
Jin, J., Yao, Z., Qin, H., Wang, K., Xin, X., Bufalin inhibits the malignant development of non-small cell lung cancer by mediating the Circ_0046264/MiR-522-3p axis. Biotechnol. Lett. 43 (2021), 1229–1240, 10.1007/s10529-021-03081-6.
Zhai, X., Fang, F., Liu, Q., Meng, Y., Guo, Y., Chen, Z., MiR-181a contributes to bufalin-induced apoptosis in PC-3 prostate cancer cells. BMC Complement. Altern. Med., 13, 2013, 325, 10.1186/1472-6882-13-325.
Zhao, H., Zhao, D., Tan, G., Liu, Y., Zhuang, L., Liu, T., Bufalin promotes apoptosis of gastric cancer by down-regulation of MiR-298 targeting bax. Int. J. Clin. Exp. Med. 8 (2015), 3420–3428.
Qiu, Y., Hu, Q., Tang, Q., Feng, W., Hu, S., Liang, B., Peng, W., Yin, P., MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 35 (2014), 2599–2606, 10.1007/s13277-013-1342-6.
Liu, T., Wu, C., Weng, G., Zhao, Z., He, X., Fu, C., Sui, Z., Huang, S.-X., Bufalin Inhibits Cellular Proliferation and Cancer Stem Cell-Like Phenotypes via Upregulation of MiR-203 in Glioma. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 44 (2017), 671–681, 10.1159/000485279.
Chang, Y., Zhao, Y., Gu, W., Cao, Y., Wang, S., Pang, J., Shi, Y., Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through Mir-148a. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 36 (2015), 1186–1196, 10.1159/000430289.
Zhang, L., Yoshida, T., Kuroiwa, Y., Stimulation of melanin synthesis of B16-F10 mouse melanoma cells by bufalin. Life Sci. 51 (1992), 17–24, 10.1016/0024-3205(92)90213-9.
Zhang, L., Nakaya, K., Yoshida, T., Kuroiwa, Y., Induction by Bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res. 52 (1992), 4634–4641.
Zhang, L.S., Nakaya, K., Yoshida, T., Kuroiwa, Y., Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 178 (1991), 686–693, 10.1016/0006-291x(91)90162-z.
Yamada, K., Hino, K., Tomoyasu, S., Honma, Y., Tsuruoka, N., Enhancement by Bufalin of retinoic acid-induced differentiation of acute promyelocytic leukemia cells in primary culture. Leuk. Res. 22 (1998), 589–595, 10.1016/s0145-2126(98)00044-7.
Numazawa, S., Inoue, N., Nakura, H., Sugiyama, T., Fujino, E., Shinoki, M., Yoshida, T., Kuroiwa, Y., A cardiotonic steroid bufalin-induced differentiation of THP-1 Cells. Involvement of Na+, K(+)-ATPase inhibition in the early changes in proto-oncogene expression. Biochem. Pharmacol. 52 (1996), 321–329, 10.1016/0006-2952(96)00210-9.
Szabo, E., Francis, J., Birrer, M.J., Alterations in differentiation and apoptosis induced by bufalin in CJun overexpressing U-937 cells. Int. J. Oncol. 12 (1998), 403–409, 10.3892/ijo.12.2.403.
Amano, Y., Cho, Y., Matsunawa, M., Komiyama, K., Makishima, M., Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J. Steroid Biochem. Mol. Biol. 114 (2009), 144–151, 10.1016/j.jsbmb.2009.01.022.
Wang, H., Ning, Z., Li, Y., Zhu, X., Meng, Z., Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via hedgehog signaling. Mol. Med. Rep. 14 (2016), 1907–1914, 10.3892/mmr.2016.5471.
Chang, Y., Zhao, Y., Zhan, H., Wei, X., Liu, T., Zheng, B., Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line HMG63-derived cancer stem cells. Tumor Biol. 35 (2014), 1075–1082, 10.1007/s13277-013-1143-y.
Wang, J., Cai, H., Xia, Y., Wang, S., Xing, L., Chen, C., Zhang, Y., Xu, J., Yin, P., Jiang, Y., et al. Bufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression. Oncotarget 9 (2018), 23320–23333, 10.18632/oncotarget.24157.
Wang, H., Zhang, C., Xu, L., Zang, K., Ning, Z., Jiang, F., Chi, H., Zhu, X., Meng, Z., Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/MTOR pathway. Oncotarget 7 (2016), 20193–20208, 10.18632/oncotarget.7935.
Zhao, L., Liu, S., Che, X., Hou, K., Ma, Y., Li, C., Wen, T., Fan, Y., Hu, X., Liu, Y., et al. Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors. Int. J. Mol. Med. 36 (2015), 645–652, 10.3892/ijmm.2015.2268.
Zhang, D.-M., Feng, L.-X., Liu, M., Jin, W.-H., Luo, J., Nie, A.-Y., Zhou, Y., Li, Y., Wu, W.-Y., Jiang, B.-H., et al. Possible target-related proteins and signal network of bufalin in A549 cells suggested by both ITRAQ-based and label-free proteomic analysis. Proteomics 16 (2016), 935–945, 10.1002/pmic.201500418.
Yang, Z., Tao, Y., Xu, X., Cai, F., Yu, Y., Ma, L., Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway. Biochem. Biophys. Res. Commun. 503 (2018), 2124–2131, 10.1016/j.bbrc.2018.07.169.
Fang, K., Zhan, Y., Zhu, R., Wang, Y., Wu, C., Sun, M., Qiu, Y., Yuan, Z., Liang, X., Yin, P., et al. Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway. J. Transl. Med., 19, 2021, 383, 10.1186/s12967-021-03058-z.
Wang, H., Zhang, C., Ning, Z., Xu, L., Zhu, X., Meng, Z., Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Int. J. Oncol. 48 (2016), 1229–1241, 10.3892/ijo.2016.3326.
Yu, Z., Li, Y., Li, Y., Zhang, J., Li, M., Ji, L., Tang, Y., Zheng, Y., Sheng, J., Han, Q., et al. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J. Immunother. Cancer, 10, 2022, e004297, 10.1136/jitc-2021-004297.
Shih, Y.-L., Chou, J.-S., Chen, Y.-L., Hsueh, S.-C., Chung, H.-Y., Lee, M.-H., Chen, C.-P., Lee, M.-Z., Hou, H.-T., Lu, H.-F., et al. Bufalin enhances immune responses in leukemic mice through enhancing phagocytosis of macrophage in vivo. Vivo Athens Greece 32 (2018), 1129–1136, 10.21873/invivo.11355.
Fu, R., Yu, F., Wu, W., Liu, J., Li, J., Guo, F., Xu, L., Wang, F., Cui, X., Bufalin enhances the killing efficacy of NK Cells against hepatocellular carcinoma by inhibiting MICA shedding. Int. Immunopharmacol., 101, 2021, 108195, 10.1016/j.intimp.2021.108195.
Ji, D., Liang, Z., Liu, G., Zhao, G., Fang, J., Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. Naunyn. Schmiede Arch. Pharmacol. 390 (2017), 1211–1219, 10.1007/s00210-017-1419-7.
Wen, L., Huang, Y., Xie, X., Huang, W., Yin, J., Lin, W., Jia, Q., Zeng, W., Anti-inflammatory and antinociceptive activities of bufalin in rodents. Mediat. Inflamm., 2014, 2014, 171839, 10.1155/2014/171839.
Fujii, E., Inada, Y., Kakoki, M., Nishimura, N., Endo, S., Fujiwara, S., Wada, N., Kawano, Y., Okuno, Y., Sugimoto, T., et al. Bufalin induces DNA damage response under hypoxic condition in myeloma cells. Oncol. Lett. 15 (2018), 6443–6449, 10.3892/ol.2018.8091.
Jing, Y., Ohizumi, H., Kawazoe, N., Hashimoto, S., Masuda, Y., Nakajo, S., Yoshida, T., Kuroiwa, Y., Nakaya, K., Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn. J. Cancer Res. Gann 85 (1994), 645–651, 10.1111/j.1349-7006.1994.tb02408.x.
Lin, S., Lv, J., Peng, P., Cai, C., Deng, J., Deng, H., Li, X., Tang, X., Bufadienolides induce P53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo. Oncol. Lett. 15 (2018), 1566–1572, 10.3892/ol.2017.7457.
Han, K.-Q., Huang, G., Gu, W., Su, Y.-H., Huang, X.-Q., Ling, C.-Q., Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J. Gastroenterol. WJG 13 (2007), 3374–3379, 10.3748/wjg.v13.i24.3374.
Cao, F., Gong, Y.-B., Kang, X.-H., Lu, Z.-H., Wang, Y., Zhao, K.-L., Miao, Z.-H., Liao, M.-J., Xu, Z.-Y., Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicol. Appl. Pharmacol., 379, 2019, 114662, 10.1016/j.taap.2019.114662.
Strauss, M., Smith, W., Fedorova, O.V., Schutte, A.E., The Na+K+-ATPase inhibitor marinobufagenin and early cardiovascular risk in humans: a review of recent evidence. Curr. Hypertens. Rep., 21, 2019, 38, 10.1007/s11906-019-0942-y.
Shao, H., Li, B., Li, H., Gao, L., Zhang, C., Sheng, H., Zhu, L., Novel strategies for solubility and bioavailability enhancement of bufadienolides. Molecules, 27, 2021, 51, 10.3390/molecules27010051.
Yang, Z., Liu, J., Huang, Q., Zhang, Z., Zhang, J., Pan, Y., Yang, Y., Cheng, D., Radiosynthesis and pharmacokinetics of [18F]Fluoroethyl Bufalin in hepatocellular carcinoma-bearing mice. OncoTargets Ther. 10 (2017), 329–338, 10.2147/OTT.S110281.
Jiang, B., Cai, F., Gao, S., Meng, L., Liang, F., Dai, X., Xu, W., Chen, W., Induction of cytochrome P450 3A by shexiang baoxin pill and its main components. Chem. Biol. Interact. 195 (2012), 105–113, 10.1016/j.cbi.2011.12.001.
Xin, X.-L., Dong, P.-P., Sun, X.-H., Deng, S., Zhang, N., Wang, C., Huo, X.-K., Li, Y., Lan, R., Chen, L., et al. Identification of the hydroxylated derivatives of bufalin: phase I metabolites in rats. J. Asian Nat. Prod. Res. 18 (2016), 239–247, 10.1080/10286020.2015.1071358.
Li, H., Xu, W., Zhang, X., Zhang, W., Hu, L., Bufalin inhibits CYP3A4 activity in vitro and in vivo. Acta Pharmacol. Sin. 30 (2009), 646–652, 10.1038/aps.2009.42.
Vangijzegem, T., Stanicki, D., Laurent, S., Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin. Drug Deliv. 16 (2019), 69–78, 10.1080/17425247.2019.1554647.
Xu, Y., Liu, Y., Liu, Q., Lu, S., Chen, X., Xu, W., Shi, F., Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy. J. Control. Release Off. J. Control. Release Soc. 338 (2021), 705–718, 10.1016/j.jconrel.2021.08.049.
Gou, H., Huang, R.-C., Zhang, F.-L., Su, Y.-H., Design of dual targeting immunomicelles loaded with bufalin and study of their anti-tumor effect on liver cancer. J. Integr. Med. 19 (2021), 408–417, 10.1016/j.joim.2021.05.001.
Li, Y., Yuan, J., Yang, Q., Cao, W., Zhou, X., Xie, Y., Tu, H., Zhang, Y., Wang, S., Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma. Int. J. Nanomed. 9 (2014), 5683–5700, 10.2147/IJN.S73651.
Xu, Y., Tang, L., Chen, P., Chen, M., Zheng, M., Shi, F., Wang, Y., Tumor-TArgeted Delivery of Bufalin-loaded Modified Albumin-polymer Hybrid for Enhanced Antitumor Therapy and Attenuated Hemolysis Toxicity and Cardiotoxicity. AAPS PharmSciTech, 22, 2021, 137, 10.1208/s12249-021-02000-2.
Hu, H., Qi, Q., Dong, Z., Yu, X., Mo, Y., Luo, J., Wang, Y., Du, S., Lu, Y., Albumin coated trimethyl chitosan-based targeting delivery platform for photothermal/chemo-synergistic cancer therapy. Carbohydr. Polym., 241, 2020, 116335, 10.1016/j.carbpol.2020.116335.
Yuan, J., Zeng, C., Cao, W., Zhou, X., Pan, Y., Xie, Y., Zhang, Y., Yang, Q., Wang, S., Bufalin-loaded PEGylated liposomes: antitumor efficacy, acute toxicity, and tissue distribution. Nanoscale Res. Lett., 14, 2019, 223, 10.1186/s11671-019-3057-0.
Xu, J., Sun, Y., Yuan, Z., Bao, Y., Li, R., Liu, C., Qiu, Y., Xu, K., Shi, X., Yu, H., et al. Bufalin-loaded CaP/DPPE-PEG-EGF nanospheres: preparation, cellular uptake, distribution, and anti-tumor effects. J. Biomed. Nanotechnol. 15 (2019), 329–339, 10.1166/jbn.2019.2681.
Yin, P., Wang, Y., Qiu, Y., Hou, L., Liu, X., Qin, J., Duan, Y., Liu, P., Qiu, M., Li, Q., Bufalin-loaded MPEG-PLGA-PLL-CRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int. J. Nanomed. 7 (2012), 3961–3969, 10.2147/IJN.S32063.
Tian, X., Yin, H., Zhang, S., Luo, Y., Xu, K., Ma, P., Sui, C., Meng, F., Liu, Y., Jiang, Y., et al. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma. Eur. J. Pharm. Biopharm. Off. J. Arb. Pharm. Verfahr. EV 87 (2014), 445–453, 10.1016/j.ejpb.2014.05.010.
Hu, Q., Liang, B., Sun, Y., Guo, X.-L., Bao, Y.-J., Xie, D.-H., Zhou, M., Duan, Y.-R., Yin, P.-H., Peng, Z.-H., Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer. Int. J. Nanomed. 9 (2014), 4035–4041, 10.2147/IJN.S64708.
Liu, T., Yuan, X., Jia, T., Liu, C., Ni, Z., Qin, Z., Yuan, Y., Polymeric prodrug of bufalin for increasing solubility and stability: synthesis and anticancer study in vitro and in vivo. Int. J. Pharm. 506 (2016), 382–393, 10.1016/j.ijpharm.2016.04.041.
Liu, T., Jia, T., Yuan, X., Liu, C., Sun, J., Ni, Z., Xu, J., Wang, X., Yuan, Y., Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo. Int. J. Nanomed. 11 (2016), 2235–2250, 10.2147/IJN.S100404.
Zou, A., Zhao, X., Handge, U.A., Garamus, V.M., Willumeit-Römer, R., Yin, P., Folate receptor targeted bufalin/β-cyclodextrin supramolecular inclusion complex for enhanced solubility and anti-tumor efficiency of bufalin. Mater. Sci. Eng. C Mater. Biol. Appl. 78 (2017), 609–618, 10.1016/j.msec.2017.04.094.
Wang, H., Wu, J., Williams, G.R., Fan, Q., Niu, S., Wu, J., Xie, X., Zhu, L.-M., Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J. Nanobiotechnol., 17, 2019, 60, 10.1186/s12951-019-0494-y.
Zeng, H., Xia, C., Zhao, B., Zhu, M., Zhang, H., Zhang, D., Rui, X., Li, H., Yuan, Y., Folic acid–functionalized metal-organic framework nanoparticles as drug carriers improved bufalin antitumor activity against breast cancer. Front. Pharmacol., 12, 2022, 747992, 10.3389/fphar.2021.747992.
Liu, M., Feng, L.-X., Sun, P., Liu, W., Wu, W.-Y., Jiang, B.-H., Yang, M., Hu, L.-H., Guo, D.-A., Liu, X., A novel bufalin derivative exhibited stronger apoptosis-inducing effect than bufalin in A549 lung cancer cells and lower acute toxicity in mice. PLoS One, 11, 2016, e0159789, 10.1371/journal.pone.0159789.
Ren, J., Gao, X., Guo, X., Wang, N., Wang, X., Research progress in pharmacological activities and applications of cardiotonic steroids. Front. Pharmacol., 13, 2022, 902459, 10.3389/fphar.2022.902459.